Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135


Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.

Oliver MD, Fernández-Acero T, Luna S, Rodríguez-Escudero I, Molina M, Pulido R, Cid VJ.

Biosci Rep. 2017 Mar 15;37(2). pii: BSR20160258. doi: 10.1042/BSR20160258. Print 2017 Apr 30.


Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.

Layton MJ, Rynkiewicz NK, Ivetac I, Horan KA, Mitchell CA, Phillips WA.

Biosci Rep. 2014 Apr 1;34(2). pii: e00104. Print 2014 Apr 1.


Discovery and functional characterization of a neomorphic PTEN mutation.

Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR, Bustamante CD.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13976-81. doi: 10.1073/pnas.1422504112. Epub 2015 Oct 26.


Hippocampal ischemia causes deficits in local field potential and synaptic plasticity.

Wang S, Zhang J, Sheng T, Lu W, Miao D.

J Biomed Res. 2015 Sep;29(5):370-9. doi: 10.7555/JBR.29.20150010. Epub 2015 Jun 8.


Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.

Cheung LW, Walkiewicz KW, Besong TM, Guo H, Hawke DH, Arold ST, Mills GB.

Elife. 2015 Jul 29;4:e06866. doi: 10.7554/eLife.06866.


Crossroads of PI3K and Rac pathways.

Campa CC, Ciraolo E, Ghigo A, Germena G, Hirsch E.

Small GTPases. 2015;6(2):71-80. doi: 10.4161/21541248.2014.989789. Epub 2015 May 5. Review.


A method to control phosphoinositides and to analyze PTEN function in living cells using voltage sensitive phosphatases.

Mavrantoni A, Thallmair V, Leitner MG, Schreiber DN, Oliver D, Halaszovich CR.

Front Pharmacol. 2015 Mar 31;6:68. doi: 10.3389/fphar.2015.00068. eCollection 2015.


PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Thorpe LM, Yuzugullu H, Zhao JJ.

Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860. Review.


Lipid-based patterning of the immunological synapse.

Huse M.

Biochem Soc Trans. 2014 Dec;42(6):1506-11. doi: 10.1042/BST20140191. Review.


Molecular mechanisms and functional implications of polarized actin remodeling at the T cell immunological synapse.

Le Floc'h A, Huse M.

Cell Mol Life Sci. 2015 Feb;72(3):537-56. doi: 10.1007/s00018-014-1760-7. Epub 2014 Oct 30. Review.


Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Bruntz RC, Lindsley CW, Brown HA.

Pharmacol Rev. 2014 Oct;66(4):1033-79. doi: 10.1124/pr.114.009217. Review.


RAS interaction with PI3K p110α is required for tumor-induced angiogenesis.

Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J.

J Clin Invest. 2014 Aug;124(8):3601-11. doi: 10.1172/JCI74134. Epub 2014 Jul 8.


Expression of migfilin is increased in esophageal cancer and represses the Akt-β-catenin activation.

He H, Ding F, Li S, Chen H, Liu Z.

Am J Cancer Res. 2014 May 26;4(3):270-8. eCollection 2014.


Inflammation to cancer: The molecular biology in the pancreas (Review).

Ling S, Feng T, Jia K, Tian Y, Li Y.

Oncol Lett. 2014 Jun;7(6):1747-1754. Epub 2014 Mar 28.


RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.

Kawasaki J, Aegerter S, Fevurly RD, Mammoto A, Mammoto T, Sahin M, Mably JD, Fishman SJ, Chan J.

J Clin Invest. 2014 Jun;124(6):2774-84. doi: 10.1172/JCI67084. Epub 2014 May 16.


PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.

Edlind MP, Hsieh AC.

Asian J Androl. 2014 May-Jun;16(3):378-86. doi: 10.4103/1008-682X.122876. Review.


PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.

Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, Kim SW, Luvison A, Miller M, Nikiforova MN.

BMC Cancer. 2013 Dec 17;13:602. doi: 10.1186/1471-2407-13-602.


Annular PIP3 accumulation controls actin architecture and modulates cytotoxicity at the immunological synapse.

Le Floc'h A, Tanaka Y, Bantilan NS, Voisinne G, Altan-Bonnet G, Fukui Y, Huse M.

J Exp Med. 2013 Nov 18;210(12):2721-37. doi: 10.1084/jem.20131324. Epub 2013 Nov 4. Erratum in: J Exp Med. 2017 Mar 14;:. J Exp Med. 2017 Apr 3;214(4):1203.


Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.

Zhong H, Sanchez C, Spitzer D, Plambeck-Suess S, Gibbs J, Hawkins WG, Denardo D, Gao F, Pufahl RA, Lockhart AC, Xu M, Linehan D, Weber J, Wang-Gillam A.

PLoS One. 2013 Oct 9;8(10):e77243. doi: 10.1371/journal.pone.0077243. eCollection 2013. Erratum in: PLoS One. 2015;10(4):e0127365. Spitrzer, Dirk [corrected to Spitzer, Dirk].

Supplemental Content

Support Center